


Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/806,793	
				Filing Date		March 22, 2004	
				First Named Inventor		Johansen	
				Group Art Unit		1647 1649	
				Examiner Name		Sharon L. Turner Ballard	
				Attorney Docket Number		19313-001 CON	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes No	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
KAB	C26	Masure et al., "Enovin, a novel member of the GDNF family of neurotrophic growth factors with growth promoting and neuroprotective effects on neuronal cells", a poster presentation from <i>Janssen Research Foundation</i> , "Gordon Conference" held on June 6-11, 1999.					
KAB	C27	Genbank Accession No. AF120274, 1999.					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Kimberly Ballard/	Date Considered	02/28/2007
-------------------------------	--------------------	----------------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Please type a plus sign (+) in this box ☐

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/806,793	
				Filing Date		March 22, 2004	
				First Named Inventor		Johansen	
				Group Art Unit		1647 1649	
				Examiner Name		Sharon L. Turner Ballard	
				Attorney Docket Number		19313-001 CON	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
KAB	C28	Hallböök et al. <i>J. Compar. Neurol.</i> , 364:664-676 (1996)					
KAB	C29	Kirsch et al. <i>Neurosci. Lett.</i> , 180:163-166 (1994)					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Kimberly Ballard/	Date Considered	02/28/2007
-------------------------------	--------------------	----------------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) in this box



Under the Paperwork Reduction Project, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/806,793
	Filing Date	March 22, 2004
	First Named Inventor	Johansen
	Group Art Unit	1649
	Examiner Name	Sharon L. Turner Ballard
	Attorney Docket Number	19313-001 CON

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
KAB	B6	WO	00/34475	AMGEN INC.	06/15/00		

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Kimberly Ballard/	Date Considered	02/28/2007
---------------------------	--------------------	------------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Please type a plus sign (+) in this box



Approved for use through 12/31/00. OMB No. 51-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/662,183
	Filing Date	September 15, 2000
	First Named Inventor	Johansen <i>et al.</i>
	Group Art Unit	1635
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	19313-001 DIV

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
88	A1*	5,084,350	1/28/92	Chang, <i>et al.</i>			2/16/90
88	A2*	4,883,666	11/28/89	Sabel, <i>et al.</i>			4/29/87
88	A3*	5,284,761	2/8/94	Aebischer, <i>et al.</i>			2/26/92
88	A4*	5,618,531	4/8/97	Cherksey			7/13/93
88	A5*	5,916,555	6/29/99	Lee, <i>et al.</i>			10/30/97
88	A6*	5,834,029	10/10/98	Bellamkonda, <i>et al.</i>			7/20/94
88	A7*	5,496,804	3/5/96	Reed, <i>et al.</i>			10/21/94
88	A8*	5,795,716	8/18/98	Chee, <i>et al.</i>			10/21/94
88	A9*	5,754,524	5/19/98	Wark			10/30/96
88	A10*	5,733,729	3/31/98	Lipshutz, <i>et al.</i>			9/14/95
88	A11*	5,800,992	9/1/98	Fodor, <i>et al.</i>			6/25/96

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
88	B1*	WO 93/06116	Lin, <i>et al.</i>	4/1/93	X
88	B2*	WO 97/08196	Johnson, <i>et al.</i>	3/6/97	X
88	B3*	WO 98/32569	Johansen, <i>et al.</i>	7/30/98	X

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
88	C1*	Safer and Oertel, 1994. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. <i>Neuroscience</i> 59: 401-415.
88	C2*	Baloh, <i>et al.</i> , 1998. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRα3-RET receptor complex. <i>Neuron</i> 21: 1291-1302, December.
88	C3*	Milbrandt, <i>et al.</i> , 1998. Persephin, a novel neurotrophic factor related to GDNF and neurturin. <i>Neuron</i> 20: 245-253, Feb.
88	C4*	Airaksinen, <i>et al.</i> , 1999. GDNF family neurotrophic factor signaling: Four masters, one servant? <i>Mol. Cell. Neurosci.</i> 13: 313-325.
88	C5*	Atschul, <i>et al.</i> , 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. <i>Nucl. Acids Res.</i> 25: 3389-3402.
88	C6*	Thompson, <i>et al.</i> , 1997. The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality

58
6-11-01
58
6-11-01



OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initial	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		analysis tools. <i>Nuc. Acids Res.</i> 25: 4876-4882.
85	C7*	Eigenbrot and Gerber, 1997. X-ray structure of glial cell-derived neurotrophic factor at 1.9 A resolution and implications for receptor binding. <i>Nat. Struct. Biol.</i> 4: 435-438.
80	C8*	Lorenz, et al., 1996. Heteromultimeric CLC chloride channels with novel properties. <i>Proc. Natl. Acad. Sci.</i> 93: 13362-13366.
85	C9*	Borodovsky, et al., 1995. Detection of new genes in a bacterial genome using Markov models for three gene classes. <i>Nuc. Acids Res.</i> 23: 3554-3562.
80	C10*	Finsen, et al., 1992. Somatostatin and neuropeptide Y in organotypic slice cultures of the rat hippocampus: an immunocytochemical and in situ hybridization study. <i>Neurosci.</i> 47:105-113.
85	C11*	Slooth and Gramsbergen, 1995. Detection of salicylate and its hydroxylated adducts 2,3- and 2,5-dihydroxybenzoic acids as possible indices for in vivo hydroxyl radical formation in combination with catechol- and indoleamines and their metabolites in cerebrospinal fluid and brain tissue. <i>J. Neurosci. Meth.</i> 60: 141-149.
80	C12*	Daopin, et al., 1993. Crystal structure of TGF- β 2 refined at 1.8 A resolution. <i>Proteins</i> 17: 176-192.
80	C13*	Sanicola, et al., 1997. Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins. <i>Proc Natl Acad Sci USA</i> 94: 6238-6243.
85	C14*	Stoppini, et al., 1991. A simple method for organotypic cultures of nervous tissue. <i>J. Neurosci. Methods</i> 37: 173-182.
80	C15*	Zufferey, et al., 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. <i>Nat. Biotechnol.</i> 1997 15: 871-875.
80	C16*	von Schwedler, et al., 1993. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. <i>J. Virol.</i> 67: 4945-4955.
85	C17*	Masure et al., Enovin, a member of the glial cell-line-derived neurotrophic factor (GDNF) family with growth promoting activity on neuronal cells. <i>Eur. J. Biochem.</i> 266: 892-902 (1999).
80	C18*	Robertson and Manson, The GDNF-RET signalling in partnership. <i>Trends Genet.</i> 13: 1-3 (1997).
85	C19*	Lapchak, Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. <i>Rev. Neurosci.</i> 7: 165-176 (1997).
80	C20*	Unsicker, GDNF: a cytokine at the interface of TGF- β and neurotrophins. <i>Cell Tissue Res.</i> 286: 175-178 (1996).
85	C21*	Lapchak, et al., Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. <i>Cell Tissue Res.</i> 286: 179-189 (1996).
80	C22*	Nucleotide Sequence Database EMBL Entry XA844072, Accession No. AA844072. 3-10-1998
85	C23*	Massagué, et al., 1994. The TGF- β family and its composite receptor. <i>Trends Cell Biol.</i> 4: 172-178.
80	C24*	McDonald & Hendrickson, 1993. A structural superfamily of growth factors containing a cystine knot motif. <i>Cell</i> 73: 421-424.
80	C25*	Lin, et al., 1993. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. <i>Science</i> 260: 1130-1132.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/347,613, filed July 2, 1999, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	3-11-03
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRADOCS:1440290.1(%VC2011.DOC)

TECH CENTER 1600/2900

Please type a plus sign (+) in this box



Approved for use through 9/30/00, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)

Modified Form 1449/PTO

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number

09/662,183

Filing Date

September 15, 2000

First Named Inventor

Johansen et al.

Group Art Unit

1635

Examiner Name

Not Yet Assigned

Attorney Docket Number

19313-001 DIV

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
75	B4*	WO 00/04050	Janssen Pharmaceutica NV.	1/27/00	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/347,613, filed July 2, 1999, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).


Examiner Signature		Date Considered	3-11-03
-----------------------	--	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Express Mail No.: EV 2873 053 US
Date of Deposit: September 2, 2003

Please type a plus sign (+) in this box



Page 1 of 1
SEP 05 2003

TECH CENTER 1600/2900

Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/662,183
	Filing Date	September 15, 2000
	First Named Inventor	Teit E. Johansen et al.
	Group Art Unit	1647
	Examiner Name	Sharon L. Turner
	Attorney Docket Number	19313-001 DIV

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
JS	A12	6,284,540	9/04/01	Milbrandt et al.	435/455		
JS	A13	20020002269 A1	Not issued	Milbrandt et al.			

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
JS	B5		WO 00/18799	Washington University	6 April 2000	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	12-2-03
---------------------------	--	------------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

NYC 270144v1

Notice of References Cited

Application/Control No.

09/347,613

Applicant(s)/Patent Under
Reexamination
JOHANSEN ET AL.

Examiner

Sumesh kaushal

Art Unit

1633

Page 1 of 3

U.S. PATENT DOCUMENTS

*		Document Number		Date MM-YYYY	Name	Classification	
		Country Code	Number-Kind Code				
	A	US-					
	B	US-					
	C	US-					
	D	US-					
	E	US-					
	F	US-					
	G	US-					
	H	US-					
	I	US-					
	J	US-					
	K	US-					
	L	US-					
	M	US-					

FOREIGN PATENT DOCUMENTS

*		Document Number		Date MM-YYYY	Country	Name	Classification	
		Country Code	Number-Kind Code					
	N							
	O							
	P							
	Q							
	R							
	S							
	T							

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Rosenberg et al., Gene therapist, heal thyself, 2000, SCIENCE, Vol. 287, p. 1751
	V	Verma, Gene therapy: Beyond 2000, 2000, MOLECULAR THERAPY, Vol. 6, pp. 493
	W	Friedmann, Principles for human gene therapy studies, 2000, SCIENCE, Vol. 287, pp. 2163-2164
	X	Anderson, Human gene therapy, 1998, NATURE, Vol. 392, pp. 25-30

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited

Application/Control No.

09/347,613

Applicant(s)/Patent Under

Reexamination

JOHANSEN ET AL.

Examiner

Sumesh kaushal

Art Unit

1633

Page 2 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Verma et al., Gene therapy-promises, problems and prospects, 1997, NATURE, pp. 239-242
	V	Varmus, Gene therapy: Not ready for prime time, 1996, NATURE MEDICINE, Vol. 2, pp. 7-8
	W	Airaksinen et al., GDNF family neurotrophic factor signalling: Four masters, one servant?, 1999, MOLECULAR AND CELLULAR NEUROSCIENCE, Vol. 13, pp. 313-325
	X	Rosenblad et al., In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin, 2000, MOLECULAR AND CELLULAR NEUROSCIENCE, Vol. 15, pp. 199-214

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited

Application/Control No.

09/347,613

Applicant(s)/Patent Under

Reexamination

JOHANSEN ET AL.

Examiner

Sumesh kaushal

Art Unit

1633

Page 3 of 3

U.S. PATENT DOCUMENTS

*		Document Number		Date MM-YYYY	Name	Classification	
		Country	Code-Number-Kind Code				
	A	US-					
	B	US-					
	C	US-					
	D	US-					
	E	US-					
	F	US-					
	G	US-					
	H	US-					
	I	US-					
	J	US-					
	K	US-					
	L	US-					
	M	US-					

FOREIGN PATENT DOCUMENTS

*		Document Number		Date MM-YYYY	Country	Name	Classification	
		Country	Code-Number-Kind Code					
	N							
	O							
	P							
	Q							
	R							
	S							
	T							

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)					
	U	During et al., Towards gene therapy for the central nervous system, 1998, MOLECULAR MEDICINE, Vol. 11. pp. 485-493					
	V	AC005051, Waterston, 1998					
	W	AF0G7197, Li, 1998					
	X	KAN40033, Gray et al., 1992					

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.